昆药集团
(600422)
| 流通市值：121.12亿 | | | 总市值：121.12亿 |
| 流通股本：7.57亿 | | | 总股本：7.57亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,608,452,032.42 | 8,401,447,233.37 | 5,457,454,882.94 | 3,554,421,628.96 |
| 营业收入 | 1,608,452,032.42 | 8,401,447,233.37 | 5,457,454,882.94 | 3,554,421,628.96 |
| 二、营业总成本 | 1,490,477,668.68 | 7,550,203,664.56 | 5,001,893,407.76 | 3,302,177,686.87 |
| 营业成本 | 1,014,740,498.5 | 4,750,196,536.29 | 3,224,711,276.3 | 2,093,421,272.54 |
| 税金及附加 | 14,112,985.06 | 81,931,448.28 | 52,889,408.55 | 35,529,313.46 |
| 销售费用 | 341,535,462.86 | 2,226,082,369.4 | 1,418,514,480 | 976,057,518.5 |
| 管理费用 | 86,280,268.09 | 371,243,797.11 | 228,950,764.83 | 148,045,124.22 |
| 研发费用 | 22,356,968.35 | 106,761,340.29 | 60,014,539.23 | 38,137,405.53 |
| 财务费用 | 11,451,485.82 | 13,988,173.19 | 16,812,938.85 | 10,987,052.62 |
| 其中:利息费用 | 13,732,056.89 | 26,361,325 | 19,629,866.98 | 13,168,883.6 |
| 其中:利息收入 | 3,344,275.54 | 12,843,782.47 | 6,642,226.89 | 4,330,355.95 |
| 加:公允价值变动收益 | 194,273.91 | 6,915,856.46 | -176,072.35 | 2,082,746.44 |
| 加:投资收益 | -218,160.08 | 14,933,233.77 | 12,246,296.01 | 9,176,440 |
| 资产处置收益 | -771.95 | 1,012,610.84 | 261,494.05 | 363,894.7 |
| 资产减值损失(新) | -2,934,870.47 | -21,954,873.58 | -14,670,900.64 | -14,997,501.35 |
| 信用减值损失(新) | 9,095,275.76 | -45,994,595.2 | -52,062,124.86 | -37,167,086.68 |
| 其他收益 | 24,353,834.91 | 121,390,832.77 | 85,686,902.79 | 71,931,700.1 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 148,463,945.82 | 927,546,633.87 | 486,847,070.18 | 283,634,135.3 |
| 加:营业外收入 | 2,067,494.82 | 3,925,293.54 | 4,508,338.29 | 2,770,528.55 |
| 减:营业外支出 | 1,427,529.21 | -3,098,310.94 | -6,150,692.16 | 1,977,869.74 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 149,103,911.43 | 934,570,238.35 | 497,506,100.63 | 284,426,794.11 |
| 减:所得税费用 | 35,551,469.84 | 183,349,572.79 | 106,993,019.77 | 50,720,444.06 |
| 六、净利润 | 113,552,441.59 | 751,220,665.56 | 390,513,080.86 | 233,706,350.05 |
| 持续经营净利润 | 113,552,441.59 | 751,220,665.56 | 390,513,080.86 | 233,706,350.05 |
| 归属于母公司股东的净利润 | 90,482,321.86 | 648,081,341.92 | 387,395,872.22 | 229,483,348.45 |
| 少数股东损益 | 23,070,119.73 | 103,139,323.64 | 3,117,208.64 | 4,223,001.6 |
| (一)基本每股收益 | 0.12 | 0.86 | 0.51 | 0.3 |
| (二)稀释每股收益 | 0.12 | 0.86 | 0.51 | 0.3 |
| 八、其他综合收益 | 1,281,044.33 | -3,926,635.37 | -987,127.81 | -89,266 |
| 归属于母公司股东的其他综合收益 | 1,295,331.14 | -3,671,171.18 | -915,314.42 | -58,384.82 |
| 九、综合收益总额 | 114,833,485.92 | 747,294,030.19 | 389,525,953.05 | 233,617,084.05 |
| 归属于母公司股东的综合收益总额 | 91,777,653 | 644,410,170.74 | 386,480,557.8 | 229,424,963.63 |
| 归属于少数股东的综合收益总额 | 23,055,832.92 | 102,883,859.45 | 3,045,395.25 | 4,192,120.42 |
| 公告日期 | 2025-04-29 | 2025-03-12 | 2024-10-26 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |